Evidence map›Paper›PMID 21439906›Full record

ReviewCurrent opinion in pharmacology2011

Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease.

Dennis L Murphy, Pablo R Moya

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Epigenetic constraints and enhancer innovation link neuronal plasticity to evolutionary adaptation.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Nutrients · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Brain Plasma Membrane Monoamine Transporter in Health and Disease.Handbook of experimental pharmacology · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dennis L MurphyLaboratory of Clinical Science, NIMH Intramural Research Program, Bethesda, MD 20892, USA. dm30h@nih.gov
Pablo R Moya
Office of Extramural Research · US

Funding

Genetic Mouse Models for the Study of Serotonin Function and BehaviorZIAMH000332 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI MURPHY, DENNIS L · 2009 to 2014
$4.9M
The Genetics of Obsessive Compulsive Disorder and Related OCD Spectrum DisordersZIAMH000336 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI MURPHY, DENNIS L · 2009 to 2014
$4.8M
THE PSYCHOLBIOLOGY AND TREATMENT OF OBESSIVE-COMPULSIVE DISORDER IN ADULTSZ01MH000336 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI MURPHY, DENNIS L · 1985 to 2008
$937k
Intramural NIH HHS Z01 MH000336Intramural NIH HHS ZIA MH000336
6 · The paper itself

Abstract

Recent major findings from studies of SLC6A4 and its corresponding protein, the serotonin (5-HT) transporter (SERT) in humans, rodents and non-human primates indicate that combinations of SLC6A4 non-coding 5', 3' UTRs and intronic regions plus coding variants acting together can change 5HT transport as much as 40-fold in vitro. In vivo, SLC6A4 variants in humans and other species lead to marked physiological changes, despite mitigating neurodevelopmental adaptations in 5-HT receptors plus compensatory alterations in 5-HT synthesis and metabolism. Polymorphisms in SLC6A4 are associated with differences in emotional, endocrine, and personality characteristics as well as many diseases. This gene, in combinations with gene×gene (G×G) and gene×environment (G×E) interactions nonetheless remains incompletely understood, with some association findings remaining controversial. Considering its primary importance in the regulation and function of the entire serotonergic system (as evidenced by the consequences of SERT-mediated reuptake inhibition by SRIs like fluoxetine in humans and of genetically engineered changes in mice and rats), it seems likely that SLC6A4 and SERT will remain areas of high interest in our field's attempts to better understand and treat 5-HT-related disorders.

Indexed as

3' Untranslated RegionsAnimalsEnvironmentGene Expression RegulationGenomic Structural VariationHumansPharmacogeneticsReceptors, SerotoninSerotoninSerotonin Plasma Membrane Transport Proteins3' Untranslated RegionsReceptors, SerotoninSerotoninSerotonin Plasma Membrane Transport ProteinsSLC6A4 protein, humanSlc6a4 protein, mouse

Identifiers

PMID21439906
PMCPMC3487694
OpenAlexW2057860544

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.